Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
This is single-arm, open-label study design. Patients will receive brigatinib until disease
progression, unacceptable toxicity, withdrawal of consent, of death.
Phase:
Phase 2
Details
Lead Sponsor:
Ji-youn Han
Collaborators:
Seoul National University Bundang Hospital Seoul National University Hospital Severance Hospital